Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 235

1.

Higher lipoprotein-associated phospholipase A2 levels are associated with coronary atherosclerosis documented by coronary angiography.

Dohi T, Miyauchi K, Ohkawa R, Nakamura K, Thuboi S, Ogita M, Miyazaki T, Nishino A, Yokoyama K, Kurata T, Yatomi Y, Daida H.

Ann Clin Biochem. 2012 Nov;49(Pt 6):527-33. doi: 10.1258/acb.2012.011252. Epub 2012 Aug 29.

PMID:
22933444
2.

Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments.

Charniot JC, Khani-Bittar R, Albertini JP, Giral P, Cherfils C, Cosson C, Guillerm E, Leprince P, Gandjbakhch I, Bonnefont-Rousselot D.

Int J Cardiol. 2013 Sep 20;168(1):132-8. doi: 10.1016/j.ijcard.2012.09.054. Epub 2012 Oct 24.

PMID:
23103135
3.

Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) in acute coronary syndrome: relationship with low-density lipoprotein cholesterol.

Jabor B, Choi H, Ruel I, Hafiane A, Mourad W, Genest J.

Can J Cardiol. 2013 Dec;29(12):1679-86. doi: 10.1016/j.cjca.2013.09.026. Epub 2013 Oct 2.

PMID:
24267807
4.

Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease.

Sabatine MS, Morrow DA, O'Donoghue M, Jablonksi KA, Rice MM, Solomon S, Rosenberg Y, Domanski MJ, Hsia J; PEACE Investigators.

Arterioscler Thromb Vasc Biol. 2007 Nov;27(11):2463-9. Epub 2007 Aug 31.

5.
6.

Plasma Lp-PLA2 in acute coronary syndrome: association with major adverse cardiac events in a community-based cohort.

Li N, Li S, Yu C, Gu S.

Postgrad Med. 2010 Jul;122(4):200-5. doi: 10.3810/pgm.2010.07.2187.

PMID:
20675983
7.

Utility of lipoprotein-associated phospholipase A2 for prediction of 30-day major adverse coronary event in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention.

Stankovic S, Asanin M, Trifunovic D, Majkic-Singh N, Miljković A, Ignjatovic S, Mrdovic I, Matic D, Savic L, Ostojic M, Vasiljevic Z.

Clin Lab. 2012;58(11-12):1135-44.

PMID:
23289182
8.

Lipoprotein-associated phospholipase A2 is related to risk of subclinical atherosclerosis but is not supported by Mendelian randomization analysis in a general Japanese population.

Ueshima H, Kadowaki T, Hisamatsu T, Fujiyoshi A, Miura K, Ohkubo T, Sekikawa A, Kadota A, Kadowaki S, Nakamura Y, Miyagawa N, Okamura T, Kita Y, Takashima N, Kashiwagi A, Maegawa H, Horie M, Yamamoto T, Kimura T, Kita T; ACCESS and SESSA Research Groups.

Atherosclerosis. 2016 Mar;246:141-7. doi: 10.1016/j.atherosclerosis.2015.12.027. Epub 2015 Dec 23.

PMID:
26775119
9.

Association of Lp-PLA2 with digital reactive hyperemia, coronary flow reserve, carotid atherosclerosis and arterial stiffness in coronary artery disease.

Ikonomidis I, Kadoglou NN, Tritakis V, Paraskevaidis I, Dimas K, Trivilou P, Papadakis I, Tzortzis S, Triantafyllidi H, Parissis J, Anastasiou-Nana M, Lekakis J.

Atherosclerosis. 2014 May;234(1):34-41. doi: 10.1016/j.atherosclerosis.2014.02.004. Epub 2014 Feb 18.

PMID:
24594367
10.

Polyunsaturated omega-3 fatty acids reduce lipoprotein-associated phospholipase A(2) in patients with stable angina.

Gajos G, Zalewski J, Mostowik M, Konduracka E, Nessler J, Undas A.

Nutr Metab Cardiovasc Dis. 2014 Apr;24(4):434-9. doi: 10.1016/j.numecd.2013.09.011. Epub 2013 Nov 1.

PMID:
24555913
11.

Relationship between plasma phospholipase A2 concentrations and lipoprotein subfractions in patients with stable coronary artery disease.

Xu RX, Zhang Y, Li XL, Li S, Guo YL, Dong Q, Liu G, Li JJ.

Clin Chim Acta. 2015 Jun 15;446:195-200. doi: 10.1016/j.cca.2015.04.032. Epub 2015 Apr 28.

PMID:
25934512
12.

Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases: a cross-sectional study of Chinese population.

Cai A, Li G, Chen J, Li X, Li L, Zhou Y.

BMC Cardiovasc Disord. 2015 Feb 26;15:14. doi: 10.1186/s12872-015-0001-9.

13.

The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.

Mohler ER 3rd, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, Johnson JL, Zalewski A; Darapladib Investigators.

J Am Coll Cardiol. 2008 Apr 29;51(17):1632-41. doi: 10.1016/j.jacc.2007.11.079.

14.

Evaluation of lipoprotein-associated phosholipase A2 and plaque burden/composition in young adults.

Celik O, Ozturk D, Akin F, Satilmis S, Yalcin AA, Erturk M, Ayca B, Akturk F, Birand A, Pusuroglu H, Kaya MG.

Coron Artery Dis. 2015 May;26(3):266-71. doi: 10.1097/MCA.0000000000000224.

PMID:
25647459
15.

Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study.

Kiechl S, Willeit J, Mayr M, Viehweider B, Oberhollenzer M, Kronenberg F, Wiedermann CJ, Oberthaler S, Xu Q, Witztum JL, Tsimikas S.

Arterioscler Thromb Vasc Biol. 2007 Aug;27(8):1788-95. Epub 2007 May 31.

16.

Lipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach: the North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II).

Möckel M, Müller R, Vollert J, Müller C, Danne O, Gareis R, Störk T, Dietz R, Koenig W.

Clin Res Cardiol. 2007 Sep;96(9):604-12. Epub 2007 Jun 27.

PMID:
17593313
17.

[Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?].

Sertić J, Skorić B, Lovrić J, Bozina T, Reiner Z.

Acta Med Croatica. 2010 Oct;64(4):237-45. Review. Croatian.

PMID:
21688606
18.

Lipoprotein-associated phospholipase A2, a novel cardiovascular inflammatory marker, in HIV-infected patients.

Mangili A, Ahmad R, Wolfert RL, Kuvin J, Polak JF, Karas RH, Wanke CA.

Clin Infect Dis. 2014 Mar;58(6):893-900. doi: 10.1093/cid/cit815. Epub 2013 Dec 11.

19.

Decreased circulating lipoprotein-associated phospholipase A2 levels are associated with coronary plaque regression in patients with acute coronary syndrome.

Dohi T, Miyauchi K, Okazaki S, Yokoyama T, Ohkawa R, Nakamura K, Yanagisawa N, Tsuboi S, Ogita M, Yokoyama K, Kurata T, Yatomi Y, Daida H.

Atherosclerosis. 2011 Dec;219(2):907-12. doi: 10.1016/j.atherosclerosis.2011.09.019. Epub 2011 Sep 17.

PMID:
22024276
20.

Association of lipoprotein-associated phospholipase A2 with coronary calcification among American and Japanese men.

El-Saed A, Sekikawa A, Zaky RW, Kadowaki T, Takamiya T, Okamura T, Edmundowicz D, Kita Y, Kuller LH, Ueshima H.

J Epidemiol. 2007 Nov;17(6):179-85.

Supplemental Content

Support Center